TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study
Open Access
- 23 June 2005
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (7) , 1503-1510
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefactThrombosis and Haemostasis, 2005
- Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2004
- Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithmEuropean Journal of Human Genetics, 2004
- Endothelial Cell Markers and the Risk of Coronary Heart DiseaseCirculation, 2004
- Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assaysBritish Journal of Haematology, 2004
- Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME StudyJournal of Thrombosis and Haemostasis, 2003
- C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Development of a Genotype 325–Specific proCPU/TAFI ELISAArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Thr325Ile polymorphism of the TAFI gene does not influence the risk of myocardial infarctionBlood, 2002
- Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.Circulation, 1994